3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Neoplasms
10
Carcinoma, Renal Cell
9
Ovarian Neoplasms
7
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Lymphoma
3
Lung Neoplasms
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Kidney Diseases
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Interventions
tislelizumab
4
talazoparib
4
pembrolizumab
4
Docetaxel
4
Nivolumab
3
PM 01183
2
MLN 8237
2
Itraconazole
2
Fluorouracil
2
Cisplatin
2
Carboplatin
2
zimberelimab
1
utomilumab
1
urelumab
1
ulixertinib
1
trifluridine tipiracil drug combination
1
sitravatinib
1
sapanisertib
1
pexidartinib
1
pevonedistat
1
peposertib
1
niraparib
1
mogamulizumab
1
lenvatinib
1
ixabepilone
1
eribulin
1
durvalumab
1
dalotuzumab
1
avelumab
1
ascrinvacumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Solid Tumors
×
avelumab
×
Clear all
NCT02994953
2024-09-20
COMBO
EMD Serono
Phase 1
Terminated
52 enrolled
34 charts